Silo Pharma said that it is planning to develop an intranasal formulation of its SPC-15, which includes “ketamine compositions,” for the prevention and treatment of stress disorders, including anxiety and PTSD. The formulation was developed at Columbia University under a sponsored research agreement. According to Silo, US Patent no 11,622,948 (“Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”), which was granted earlier this year, covers “the key technology behind SPC-15 and further drug discovery.”
Silo CEO Eric Weisblum commented, “The progress of our feasibility study investigating dose strengths of SPC-15 is a significant advancement in our development work with this pipeline candidate. Results of the feasibility study will determine our selection of the manufacturing processes, and we are currently in discussions with potential delivery partners. We may also use the feasibility data for upcoming studies related to our SPC-14 therapeutic targeting Alzheimer’s disease.”
Read the Silo Pharma press release.
